Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R De Groot

Showing results (391-400 of 467) with videos related to

Pageof 47
Sort By:
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) studyRaffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
JACC. Clinical Electrophysiology|March 23, 2019
Additional Ganglion Plexus Ablation During Thoracoscopic Surgical Ablation of Advanced Atrial Fibrillation: Intermediate Follow-Up of the AFACT StudyWouter R Berger, Jolien Neefs, Nicoline W E van den Berg, et al.
Frontiers in Cardiovascular Medicine|March 19, 2025
Obese patients exhibit a greater enhancement in mental health-related quality of life compared to non-obese patients following thoracoscopic ablation of atrial fibrillationEva R Meulendijks, Manouck J M Roelofs, Tim A C de Vries, et al.
JCI Insight|August 21, 2020
Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablationJasmeet S Reyat, Winnie Chua, Victor R Cardoso, et al.
International Journal of Cardiology|May 2, 2024
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe studyPaulus Kirchhof, Ameet Bakhai, Carlo de Asmundis, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 22, 2023
The influence of atrial high-rate episodes on stroke and cardiovascular death: an updateTobias Toennis, Emanuele Bertaglia, Axel Brandes, et al.
BMC Cardiovascular Disorders|July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
American Journal of Human Genetics|August 27, 1998
Localization of the ICF syndrome to chromosome 20 by homozygosity mappingC Wijmenga, L P van den Heuvel, E Strengman, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Journal of the American College of Cardiology|September 10, 2016
Ganglion Plexus Ablation in Advanced Atrial Fibrillation: The AFACT StudyAntoine H G Driessen, Wouter R Berger, Sébastien P J Krul, et al.
Pageof 47

Showing results (391-400 of 467) with videos related to

Sort By:
Pageof 47
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 13, 2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) studyRaffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
JACC. Clinical Electrophysiology|March 23, 2019
Additional Ganglion Plexus Ablation During Thoracoscopic Surgical Ablation of Advanced Atrial Fibrillation: Intermediate Follow-Up of the AFACT StudyWouter R Berger, Jolien Neefs, Nicoline W E van den Berg, et al.
Frontiers in Cardiovascular Medicine|March 19, 2025
Obese patients exhibit a greater enhancement in mental health-related quality of life compared to non-obese patients following thoracoscopic ablation of atrial fibrillationEva R Meulendijks, Manouck J M Roelofs, Tim A C de Vries, et al.
JCI Insight|August 21, 2020
Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablationJasmeet S Reyat, Winnie Chua, Victor R Cardoso, et al.
International Journal of Cardiology|May 2, 2024
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe studyPaulus Kirchhof, Ameet Bakhai, Carlo de Asmundis, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 22, 2023
The influence of atrial high-rate episodes on stroke and cardiovascular death: an updateTobias Toennis, Emanuele Bertaglia, Axel Brandes, et al.
BMC Cardiovascular Disorders|July 14, 2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)Raffaele De Caterina, Peter Kelly, Pedro Monteiro, et al.
American Journal of Human Genetics|August 27, 1998
Localization of the ICF syndrome to chromosome 20 by homozygosity mappingC Wijmenga, L P van den Heuvel, E Strengman, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Journal of the American College of Cardiology|September 10, 2016
Ganglion Plexus Ablation in Advanced Atrial Fibrillation: The AFACT StudyAntoine H G Driessen, Wouter R Berger, Sébastien P J Krul, et al.
Pageof 47